Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

October 24, 2023

BRISBANE, Calif.--(BUSINESS WIRE)--Oct. 24, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Society of Gene & Cell Therapy (ESGCT) has accepted six Sangamo abstracts for presentation at the 30th Annual Congress being held October 24-27, 2023, in-person in Brussels, Belgium. Presentations will focus on the progression of Sangamo's pre-clinical programs, including data from its neurology epigenetic regulation programs, and advancements in the CAR-Treg pipeline.

"The data we are presenting at ESGCT reflect the important advances being made across our neurology and CAR-Treg pipelines," said Jason Fontenot, Ph.D., Chief Scientific Officer at Sangamo. "We are excited to showcase these innovations, which reinforce the potential of our science to create transformative treatments for patients suffering with serious diseases."

Data to be presented at the ESGCT Annual Congress include an oral presentation demonstrating how zinc finger activators (ZF-As) may be designed to potentially address neurodevelopmental disorders such as autism spectrum disorder and intellectual disability, for which limited therapeutic treatments currently exist. This presentation will show how ZF-As can be designed to restore normal gene and protein expression of SCN2A *in vitro* and *in vivo*. This will be accompanied by a poster presentation demonstrating Shank3 gene activation, mediated by ZF-As as a potential therapeutic approach for Phelan-McDermid syndrome. Both datasets originate from pre-clinical programs previously co-developed in partnership with Novartis.

Additional presentations at the ESGCT Annual Congress will unveil for the first time pre-clinical data showing that autologous MOG-CAR-Tregs may provide a long-lasting treatment option to potentially address the underlying cause of multiple sclerosis, as well as updated pre-clinical data evaluating IL23R-CAR-Tregs as a potentially effective treatment option to address inflammation for patients with Crohn's disease. Data will also showcase our platform capability of efficient and durable epigenetic cell engineering using compact ZF-Repressors to target immune checkpoints with the potential to improve the anti-tumor activity of T cells in cancer therapy.

ESGCT Annual Congress Presentations and Invited Sessions

Epigenetic Regulation for Neurology:

- Zinc Finger Activators restore normal gene and protein expression in a mouse model of SCN2A haploinsufficiency
  - Abstract No. OR09
  - Oral Presentation – October 24; 17:00-19:00
- Shank3 Gene Activation Mediated by Zinc Finger Activators (ZF-As) as a Therapeutic Approach for Phelan-McDermid Syndrome
  - Abstract No. P415
  - Poster Presentation – October 25; 17:00 to 18:15 and October 26; 20:30 to 21:30

Cell Therapy
Regulatory T-Cells (CAR-Tregs)

- Myelin Oligodendrocyte Glycoprotein (MOG)-CAR-Tregs – A novel approach to treat multiple sclerosis
  - Abstract No. P475
  - Poster Presentation – October 25; 17:00 to 18:15 and October 26; 20:30 to 21:30
- Evaluation of IL23R as a target for CAR-Tregs at the site of inflammation in subjects with Crohn's Disease
  - Abstract No. P487
  - Poster Presentation – October 25; 17:00 to 18:15 and October 26; 20:30 to 21:30
- Multimerization of Chimeric Antigen Receptor (CAR) binding domains: A solution to assess tissue specificity of low to medium affinity scFv
  - Abstract No. P503
  - Poster Presentation – October 25; 17:00 to 18:15 and October 26; 20:30 to 21:30

CAR-T in Oncology

- Multiplex targeting of immune checkpoints with compact zinc finger repressors to improve anti-tumor activity of T cells
  - Abstract No. P212
  - Poster Presentation – October 25; 18:15 to 19:30 and October 26; 19:30 to 20:30

All ESGCT presentations are available on the Sangamo website.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don't exist. To learn more, visit and connect with us on LinkedIn and Twitter.

Sangamo Forward Looking Statements

This press release contains forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, statements relating to Sangamo's technologies, the presentation of data from various therapeutic and research programs and the potential of these programs to demonstrate therapeutic benefit and transform the lives of patients. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the research development process, including the results of clinical trials; the regulatory approval process for product candidates; and the potential for technological developments that obviate technologies used by Sangamo. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2022. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231023250843/en/

Investor Relations & Media Inquiries
Louise Wilkie
ir@sangamo.com
media@sangamo.com

Source: Sangamo Therapeutics, Inc.